Capivasertib (AZD5363)

Name: Capivasertib (AZD5363)
Brand: Selleck Chemicals
SKU: S8019
Rating: 5 (84 reviews)

For research use only.

Catalog No.S8019

84 publications

Capivasertib (AZD5363) Chemical Structure

CAS No. 1143532-39-1

Capivasertib (AZD5363) potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

Selleck's Capivasertib (AZD5363) has been cited by 84 publications

Nature, 2020, 583(7817):620-624

PubMed: 32669709 ( click the link to review the publication )

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Cancer Cell, 2017, 32(6):869-883

PubMed: 29232557 ( click the link to review the publication )

Mol Cell, 2021, S1097-2765(21)00264-1

PubMed: 33878293 ( click the link to review the publication )

Cancer Res, 2021, canres.3232.2020

PubMed: 33685991 ( click the link to review the publication )

J Exp Clin Cancer Res, 2021, 40(1):168

PubMed: 33990217 ( click the link to review the publication )

Cell Death Dis, 2021, 12(4):400

PubMed: 33854046 ( click the link to review the publication )

Cancer Med, 2021, 10(7):2370-2379

PubMed: 33665980 ( click the link to review the publication )

Commun Biol, 2021, 4(1):416

PubMed: 33772116 ( click the link to review the publication )

Mol Cell, 2020, 80(6):1104-1122.e9

PubMed: 33259812 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5982

PubMed: 33239617 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Eur J Cancer, 2020, 126:93-103

PubMed: 31927215 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 39(1):33

PubMed: 32041631 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2500

PubMed: 32899250 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439931 ( click the link to review the publication )

Cells, 2020, 9(3)

PubMed: 32106632 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002/1878-0261.12888

PubMed: 33338300 ( click the link to review the publication )

Mol Oncol, 2020, 26

PubMed: 32336009 ( click the link to review the publication )

J Recept Signal Transduct Res, 2020, 1-11

PubMed: 33108937 ( click the link to review the publication )

Mol Cancer Res, 2020, molcanres.0623.2020

PubMed: 33303690 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.15830

PubMed: 32914934 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Sci Rep, 2020, 10(1):21762

PubMed: 33303839 ( click the link to review the publication )
Stem Cells Int, 2020, 6;2020:7073805

PubMed: 32322280 ( click the link to review the publication )

Nature, 2020, 583(7817):620-624

PubMed: 32669709 ( click the link to review the publication )

Life Sci Alliance, 2020, 31;3(5) pii: e202000648

PubMed: 32234750 ( click the link to review the publication )

Clin Transl Med, 2020, 10(1):363-373

PubMed: 32508049 ( click the link to review the publication )

Oncotarget, 2020, 17;11(11):969-981

PubMed: 32215185 ( click the link to review the publication )

FASEB Bioadv, 2020, 2(2):126-144

PubMed: 32123862 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2367-2378

PubMed: 30858154 ( click the link to review the publication )

J Hematol Oncol, 2019, 12(1):132

PubMed: 31805962 ( click the link to review the publication )

Oncogene, 2019, 38(26):5294-5307

PubMed: 30914799 ( click the link to review the publication )

EBioMedicine, 2019, 40:77-91

PubMed: 30594554 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31540244 ( click the link to review the publication )

Cancers (Basel), 2019, 30;12(1) pii: E89

PubMed: 31905918 ( click the link to review the publication )

Cell Prolif, 2019, 52(3):e12584

PubMed: 30834619 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13308

PubMed: 31527768 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5200

PubMed: 30518851 ( click the link to review the publication )

Oncogene, 2018, 10.1038/s41388-018-0498-3

PubMed: 30228349 ( click the link to review the publication )

Oncogene, 2018,

PubMed: 29059160 ( click the link to review the publication )

Gastric Cancer, 2018, 10.1007/s10120-018-0859-1

PubMed: 30066183 ( click the link to review the publication )

J Immunol, 2018, 201(5):1510-1521

PubMed: 30037846 ( click the link to review the publication )

J Proteomics, 2018, 170:130-140

PubMed: 28842319 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(7):584-589

PubMed: 29708815 ( click the link to review the publication )

Oncol Rep, 2018, 40(6):3561-3572

PubMed: 30272296 ( click the link to review the publication )

PLoS One, 2018, 13(2):e0191890

PubMed: 29389967 ( click the link to review the publication )
Nat Commun, 2017, 8(1):410

PubMed: 28871105 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(16):9654-9678

PubMed: 28934469 ( click the link to review the publication )

Dev Cell, 2017, 43(6):673-688

PubMed: 29103956 ( click the link to review the publication )

Cell Rep, 2017, 20(13):3212-3222

PubMed: 28954236 ( click the link to review the publication )

Elife, 2017, 6e30640

PubMed: 29173281 ( click the link to review the publication )

Breast Cancer Res, 2017, 19(1):74

PubMed: 28666462 ( click the link to review the publication )

J Neuroinflammation, 2017, 14(1):228

PubMed: 29178967 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(10)E2114

PubMed: 28991210 ( click the link to review the publication )

Biomed Pharmacother, 2017, 90:414-420

PubMed: 28391163 ( click the link to review the publication )

PLoS One, 2017, 12(10):e0186106

PubMed: 28982179 ( click the link to review the publication )

Immunol Lett, 2017, 184:7-14

PubMed: 28223102 ( click the link to review the publication )

Int J Gynecol Cancer, 2017, 27(2):196-205

PubMed: 27870715 ( click the link to review the publication )

Exp Ther Med, 2017, 13(6):3021-3031

PubMed: 28587375 ( click the link to review the publication )

Oncotarget, 2017, 8(6):9739-9751

PubMed: 28039457 ( click the link to review the publication )

EMBO J, 2016, 35(20):2192-2212

PubMed: 27625374 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(4):1018-27

PubMed: 26490311 ( click the link to review the publication )

Cancer Res, 2016, pii: canres.3393

PubMed: 27197158 ( click the link to review the publication )

Int J Oncol, 2016, 49(3):953-60

PubMed: 27572939 ( click the link to review the publication )

Eur J Pharmacol, 2016, 788:90-97

PubMed: 27321870 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 477(1):1-8

PubMed: 26970307 ( click the link to review the publication )

Oncol Lett, 2016, 11(3):1685-1692

PubMed: 26998062 ( click the link to review the publication )

Anticancer Res, 2016, 36(11):5849-5858

PubMed: 27793908 ( click the link to review the publication )

Oncotarget, 2016, 7(24):36971-36987

PubMed: 27175591 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13651-66

PubMed: 26871944 ( click the link to review the publication )
J Immunol Res, 2016, 2016:5281823

PubMed: 28116319 ( click the link to review the publication )

Nat Commun, 2015, 6:6750

PubMed: 25857523 ( click the link to review the publication )

Elife, 2015, 4:e10510

PubMed: 26523394 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.226

PubMed: 26165839 ( click the link to review the publication )

Oncoimmunology, 2015, 10.1080/2162402X.2015.1005448

PubMed: ( click the link to review the publication )

Hum Mol Genet, 2015, 24(23):6687-98

PubMed: 26362254 ( click the link to review the publication )

Front Oncol, 2015, 4:343

PubMed: 25520943 ( click the link to review the publication )

Anticancer Res, 2015,

PubMed: 26254364 ( click the link to review the publication )

Vanderbilt University, 2015, /

PubMed: / ( click the link to review the publication )

Cell Commun Signal, 2014, 12(1):61

PubMed: 25248616 ( click the link to review the publication )

J Biol Chem, 2014, 289(49):34189-204

PubMed: 25331943 ( click the link to review the publication )

PLoS One, 2014, 9(10):e108780

PubMed: 25360799 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description

Features

Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.

Targets

Akt1 ^[1] (Cell-free assay)	Akt2 ^[1] (Cell-free assay)	Akt3 ^[1] (Cell-free assay)	ROCK2 ^[1] (Cell-free assay)
3 nM	8 nM	8 nM	56 nM

In vitro

AZD5363 is a potent Akt inhibitor with IC50 of 3 nM, 8 nM and 8 nM for Akt1, Akt2 and Akt3, respectively. ^[1] AZD5363 inhibits phosphorylation of AKT substrates in cells with a potency of approximately 0.3 to 0.8 μM. AZD5363 inhibits the proliferation of 41 of 182 solid and hematologic tumor cell lines with a potency of < 3 μM. ^[2] Activating mutations in PIK3CA, loss or inactivation of tumor suppressor PTEN, or HER2 amplification all are significantly predictive of responsiveness to AZD5363. Additionally, correlation is also seen between the RAS mutation status of cell lines and resistance to AZD5363. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
PC-3	NFjkW5dHfW6ldHnvckBCe3OjeR?=	NGjRT5UyOCEQvF2=	M3S4UlEzKGh?	NIjBfGZqdmS3Y3XzJIF2fG:yaHHnfS=>	NEfYZ5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K1PFc1OCd-MkOyOVg4PDB:L3G+
LNCaP	MVfD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M1fWeVAuOTByMDDuUS=>	NE\EN2gxNTRiZB?=	M{f6WJJm\HWlZXSgUG5E[VBiY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVzyqB?	M1XsV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkW4O\|QxLz5{M{K1PFc1ODxxYU6=
DU145	NIO1bpdHfW6ldHnvckBCe3OjeR?=	NYXvVoE1OC53L{GvNVAh\|ryP	NXTtb5p3PDhiaB?=	M{HFV4Rwf26{ZXf1cIF1\XNidHjlJJBpd3OyaH;yfYxifGmxbjDv[kBld3ewc4Ty[YFuKHCjdHj3ZZkheHKxdHXpcpMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NILmd2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K1PFc1OCd-MkOyOVg4PDB:L3G+
PC-3	NVPheo9pTnWwY4Tpc44hSXO\|YYm=	NYPXPWdWOC53L{GvNVAh\|ryP	M3z1UlQ5KGh?	NEfZZoNld3ewcnXneYxifGW\|IITo[UBxcG:\|cHjvdplt[XSrb36gc4Yh\G:5boP0doVidSCyYYToe4F6KHC{b4TlbY5{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MnHRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NUi3OFAoRjJ\|MkW4O\|QxRC:jPh?=
C4-2	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzpNVAxNTVyMECgcm0>	NEXxTnY4OiCq	M4rkVIlv[3KnYYPld{B1cGViZoLhZ5Rqd25ib3[gZ4VtdHNidX7k[ZJod2mwZzDj[YxtKGSnYYTo	NEHuOm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m2OlYzOSd-MkO5OlY3OjF:L3G+
LNCaP	NX\MSIpZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjlVIUyODBvNUCwNEBvVQ>?	NUi0S5d5PzJiaB?=	MVrpcoNz\WG\|ZYOgeIhmKG[{YXP0bY9vKG:oIHPlcIx{KHWwZHXy[49qdmdiY3XscEBl\WG2aB?=	NH3FWWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m2OlYzOSd-MkO5OlY3OjF:L3G+
C4-2	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXxNU0yODByMDDuUS=>	NXfR[XJEOC1\|IHS=	MWPpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl4Nk[yNUc,OjN7Nk[2NlE9N2F-
LNCaP	NVzB[lNOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;kW441OS1zMECwNEBvVQ>?	NEfPZYsxNTNiZB?=	M3njRolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	MkD0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7Nk[2NlEoRjJ\|OU[2OlIyRC:jPh?=
C4-2	NGO5eG9HfW6ldHnvckBCe3OjeR?=	NGroZYs2KM7:TR?=	MoiwNE0zPCCq	NIXndYlqdmirYnn0d{BxcG:\|cHjvdplt[XSrb36gc4YhfGinIHTpd5RidCCDS2StdIF1cHejeTDibY9u[XKtZYLzJIlv[2y3ZHnu[{BRWkGVNECsJIVKTjSHLDC0SU1DWDFuIH3UU3ItKGGwZDDQO\|AhWzZia3nuZZNmKGmwIHGgeIlu\S2mZYDlcoRmdnRibXHucoVz	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl4Nk[yNUc,OjN7Nk[2NlE9N2F-
LNCaP	M1y0eGZ2dmO2aX;uJGF{e2G7	M{PNUlUh\|ryP	MYKwMVI1KGh?	NVXIV2pwcW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKHSqZTDkbZN1[WxiQVvUMZBifGi5YYmgZolwdWG{a3Xyd{BqdmOudXTpcochWFKDU{SwMEBmUUZ2RTygOGUuSlBzLDDtWG9TNCCjbnSgVFcxKFN4IHvpcoF{\SCrbjDhJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl4Nk[yNUc,OjN7Nk[2NlE9N2F-
C4-2	NUfyT\|dKTnWwY4Tpc44hSXO\|YYm=	M4TG[FUh\|ryP	NWPE[5l4OC1{NDDo	MlP1bY5lfWOnczDBT3RUPDd\|IHHu[EBCU1SWM{C4JJBpd3OyaH;yfYxifGmxbjDpckBiKHSrbXWg[IVx\W6mZX70JI1idm6nch?=	M4rWWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OU[2OlIyLz5{M{m2OlYzOTxxYU6=
LNCaP	MYfGeY5kfGmxbjDBd5NigQ>?	M1PmOFUh\|ryP	M{T5d\|AuOjRiaB?=	M{HIZYlv\HWlZYOgRWtVWzR5MzDhcoQhSUuWVEOwPEBxcG:\|cHjvdplt[XSrb36gbY4h[SC2aX3lJIRmeGWwZHXueEBu[W6wZYK=	NU\xS5hvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OlY3OjFpPkKzPVY3PjJzPD;hQi=>
PAMC82	NYWw[YxWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MX\JR\|UxRTNyIN88US=>	NF\TNYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4PFM5Oid-MkSwPFg{QDJ:L3G+
MKN74	NHz1VFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mk\uTWM2OD1\|MDFOwG0>	NXHDZ41GRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFg{QDJpPkK0NFg5Ozh{PD;hQi=>
GTL-16	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2LrSGlEPTB;M{Cg{txO	M1jSSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEi4N\|gzLz5{NEC4PFM5OjxxYU6=
SNU-5	NY\VU3BiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVvJR\|UxRTNyIN88US=>	M1LLN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEi4N\|gzLz5{NEC4PFM5OjxxYU6=
NUGC-4	Mkf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWLJR\|UxRTNyIN88US=>	NYrFTJF7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFg{QDJpPkK0NFg5Ozh{PD;hQi=>
SNU-216	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MoDZTWM2OD1\|MDFOwG0>	NHTkXm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4PFM5Oid-MkSwPFg{QDJ:L3G+
AZ521	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NV3BNYgxUUN3ME2yOU41PDhizszN	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6OEO4Nkc,OjRyOEizPFI9N2F-
NUGC-3	NVHQV5RYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1jJRmlEPTB;MkGuPFc{KM7:TR?=	MnXsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOEizPFIoRjJ2MEi4N\|gzRC:jPh?=
OCUM-1	MmLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUfJR\|UxRTF2LkWxOUDPxE1?	NVHsVHg{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFg{QDJpPkK0NFg5Ozh{PD;hQi=>
SNU-16	MnPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Ml3YTWM2OD1zMT6wPVch\|ryP	M{\ReFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEi4N\|gzLz5{NEC4PFM5OjxxYU6=
SNU-484	NYTsU5JMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFnm[VZKSzVyPUeuN\|kzKM7:TR?=	MmPxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOEizPFIoRjJ2MEi4N\|gzRC:jPh?=
KATO III	MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWnqUWJFUUN3ME23MlI3PyEQvF2=	NFzqeXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4PFM5Oid-MkSwPFg{QDJ:L3G+
HS746T	NITHTmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NE\4eIZKSzVyPU[uNFg1KM7:TR?=	M2nSflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEi4N\|gzLz5{NEC4PFM5OjxxYU6=
SNU-668	NWH3dGF6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWfEWJpWUUN3ME22MlAxOyEQvF2=	M{L0VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEi4N\|gzLz5{NEC4PFM5OjxxYU6=
SNU-601	NGXYZ\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4q5OWlEPTB;NT65N\|gh\|ryP	MmLyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOEizPFIoRjJ2MEi4N\|gzRC:jPh?=
SNU-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mmq5TWM2OD13LkK1PEDPxE1?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6OEO4Nkc,OjRyOEizPFI9N2F-
SNU-638	NFf0ToJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGXxOFdKSzVyPUSuOVI{KM7:TR?=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6OEO4Nkc,OjRyOEizPFI9N2F-
SNU-620	NWnRb3FpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEX3V2dKSzVyPUOuN\|g1KM7:TR?=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6OEO4Nkc,OjRyOEizPFI9N2F-
MKN1	Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUi2bpc5UUN3ME2yMlQzOSEQvF2=	M1;HO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEi4N\|gzLz5{NEC4PFM5OjxxYU6=
23132/87	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1jPU2lEPTB;MT62O\|Eh\|ryP	M1;rWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEi4N\|gzLz5{NEC4PFM5OjxxYU6=
NCI-N87	NIrqc25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGjzVZpKSzVyPUGuNFM4KM7:TR?=	NVnFNphPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFg{QDJpPkK0NFg5Ozh{PD;hQi=>
AGS	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NIjEV41KSzVyPUCuOVUzKM7:TR?=	NWTLbXhpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFg{QDJpPkK0NFg5Ozh{PD;hQi=>
IM95m	M2TuTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWj5R\|Z[UUN3ME2wMlUyKM7:TR?=	M1vrclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEi4N\|gzLz5{NEC4PFM5OjxxYU6=
HGC27	MoDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXjJR\|UxRTBwNES1JO69VQ>?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6OEO4Nkc,OjRyOEizPFI9N2F-
PC-9	M{\HfmZ2dmO2aX;uJGF{e2G7	NYLCSo46OS93L{GwJO69VQ>?	MkSxOE8zPCCq	NYXNV2x3cW6lcnXhd4V{KEGNVDDwbI9{eGixconsZZRqd25?	NHP3RVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm1O\|Y5Oid-MkS5OVc3QDJ:L3G+
NCI-H522	M{jMTmZ2dmO2aX;uJGF{e2G7	NEfGblkyNzVxMUCg{txO	NH\wR\|c1NzJ2IHi=	MlTQbY5kemWjc3XzJGFMXCCyaH;zdIhwenmuYYTpc44>	NF\0Oog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm1O\|Y5Oid-MkS5OVc3QDJ:L3G+
PC-9	M3;iRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFHNN3lKSzVyPUmuN{ApyrFzLkKpJO69VQ>?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl3N{[4Nkc,OjR7NUe2PFI9N2F-
NCI-H522	Mn\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NVzFW4dtUUN3ME2xNU4{KCkEsUKuO{kh\|ryP	NEHsfoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm1O\|Y5Oid-MkS5OVc3QDJ:L3G+
MR49F	M4jJb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2C2flAuPSEQvF2=	M1u0S\|Q5KGh?	M2rHZ4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF3MUCxNkc,OjVzNUGwNVI9N2F-
MR49C	NWjSPY5QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVqwMVUh\|ryP	MnO0OFghcA>?	MVLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF3MUCxNkc,OjVzNUGwNVI9N2F-
SKBR3	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjqOXNSOC1zLkO1JO69VQ>?	MWq1JIQ>	NXnIcIYx\W6qYX7j[ZMhfGinIHfyc5d1cCCrbnjpZol1cW:wIH;mJGFbTDh7M{G=	M{\tUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEm1OFc2Lz5{NkC5OVQ4PTxxYU6=
KPL4	M1;vV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M321cVAuOS5\|NTFOwG0>	NF3SVlA2KGR?	M4\5eYVvcGGwY3XzJJRp\SCpcn;3eIghcW6qaXLpeIlwdiCxZjDBXmQ5QTNz	NGD6OZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC5OVQ4PSd-Mk[wPVU1PzV:L3G+
BT474c	Moi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUj4OItWOC1zLkO1JO69VQ>?	NFjuVHc2KGR?	MV3lcohidmOnczD0bIUh\3Kxd4ToJIlvcGmkaYTpc44hd2ZiQWrEPFk{OQ>?	NYrSU4luRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPVU1PzVpPkK2NFk2PDd3PD;hQi=>
HCC1954	M3;Ifmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3Lq[FAuOS5\|NTFOwG0>	Ml3OOUBl	Mn;n[Y5p[W6lZYOgeIhmKGe{b4f0bEBqdmirYnn0bY9vKG:oIFHaSFg6OzF?	NH;CdIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC5OVQ4PSd-Mk[wPVU1PzV:L3G+
TamR	NUfjeIFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLPOFAxKG6P	NGjJ[2w3KGR?	NI\3NXNqdmO{ZXHz[YQh\HK3ZzDz[Y5{cXSrdnn0fUBw\iB2LV;IWEBidmRiZoXseoV{fHKjboS=	MnGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|NUGzNlMoRjJ4M{WxN\|I{RC:jPh?=
T74D LTED	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUCxNFAhdk1?	MoXUOkBl	NHPSRYpqdmO{ZXHz[YQh\HK3ZzDz[Y5{cXSrdnn0fUBw\iB2LV;IWEBidmRiZoXseoV{fHKjboS=	M1;nUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{WxN\|I{Lz5{NkO1NVMzOzxxYU6=
ZR75 LTED	NUPEcGZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7UXpoyODBibl2=	M37UU\|Yh\A>?	M2faV4lv[3KnYYPl[EBlenWpIIPlcpNqfGm4aYT5JI9nKDRvT1jUJIFv\CCodXz2[ZN1emGwdB?=	Mmn0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|NUGzNlMoRjJ4M{WxN\|I{RC:jPh?=
MCF7 LTED	NEjGbodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7pNlAxKG6P	MmHzOkBl	NIK0V3NqdmO{ZXHz[YQh\HK3ZzDz[Y5{cXSrdnn0fUBw\iB2LV;IWEBidmRiZoXseoV{fHKjboS=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN3MUOyN{c,OjZ\|NUGzNlM9N2F-
1%MCF7	NFu2WHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHn5bWQ1ODBibl2=	M4ix[\|Yh\A>?	NUXSO2tPcW6lcnXhd4VlKGS{dXegd4Vve2m2aY\peJkhd2ZiND3PTHQh[W6mIH\1cJZme3S{YX70	MmTFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|NUGzNlMoRjJ4M{WxN\|I{RC:jPh?=
T74D	MkX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTENVAxKG6P	MVm2JIQ>	NVHN[ppZcW6lcnXhd4VlKGS{dXegd4Vve2m2aY\peJkhd2ZiND3PTHQh[W6mIH\1cJZme3S{YX70	Ml:xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|NUGzNlMoRjJ4M{WxN\|I{RC:jPh?=
ZR75	NYr1V\|RvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLTNVAxKG6P	NH\uO2s3KGR?	NEDRWnZqdmO{ZXHz[YQh\HK3ZzDz[Y5{cXSrdnn0fUBw\iB2LV;IWEBidmRiZoXseoV{fHKjboS=	NFW1Wlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO1NVMzOyd-Mk[zOVE{OjN:L3G+
MCF7	MmTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TLOVIxOCCwTR?=	NYnxT25FPiCm	Ml3ubY5kemWjc3XkJIRzfWdic3Xud4l1cX[rdImgc4YhPC2RSGSgZY5lKG[3bI\ld5Rz[W62	NF;WTnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO1NVMzOyd-Mk[zOVE{OjN:L3G+
LNCaP	NGKwblFHfW6ldHnvckBie3OjeR?=			NWjHb2k6UW6qaXLpeIlwdiCxZjDBb5QhcW5iUGTFUk1l\W[rY3nlcpQhcHWvYX6gUG5E[VBiY3XscJMh[XO\|ZYPz[YQh[XNicHjvd5Bpd3K7bHH0bY9vKG:oIFfTT\|Nj\XSjLDDJR\|UxKD1iMD6wOkDPxE1w	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN7NEKxPEc,OjN\|OUSyNVg9N2F-
MDA-MB-468	M2DNdmZ2dmO2aX;uJIF{e2G7		NX36VlgzOiCqcoO=	NF7qdINKdmirYnn0bY9vKG:oIFHreEBqdiCqdX3hckBOTEFvTVKtOFY5KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gS3NMO2KndHGgdIhwe3Cqb4L5cIF1cW:wIHHmeIVzKDJiaILzJIJ6KGyjc3XyJJNk[W6waX7nJIN6fG:vZYTyfUwhUUN3MDC9JFAvODh7IN88UU4>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN7NEKxPEc,OjN\|OUSyNVg9N2F-
LNCaP	MkixSpVv[3Srb36gZZN{[Xl?			MmflTY5pcWKrdHnvckBw\iCDa4SgbY4hWFSHTj3k[YZq[2mnboSgbJVu[W5iTF7DZXAh[2WubIOgZZN{\XO\|ZXSgZZMheGixc4Doc5J6dGG2aX;uJI9nKFCUQWO0NEwhUUN3MDC9JFAvOjJizszNMi=>	NXj5W2pGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPVQzOThpPkKzN\|k1OjF6PD;hQi=>
BT474c	MXLGeY5kfGmxbjDhd5NigQ>?			MVjJcohq[mm2aX;uJI9nKEGtdDDpckBpfW2jbjDCWFQ4PGNiY3XscJMhcGG{Yn;ybY5oKEiHUkKrM3BKUzOFQTDkc5VjdGVibYX0ZY51KGG\|c3Xzd4VlKGG\|IIDoc5NxcG:{eXzheIlwdiCxZjDQVmFUPDBuIFnDOVAhRSByLkOxJO69VS5?	M3fheVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{m0NlE5Lz5{M{O5OFIyQDxxYU6=
MDA-MB-468	M3riRmZ2dmO2aX;uJIF{e2G7			M3jEbmlvcGmkaYTpc44hd2ZiQXv0JIlvKFCWRV6t[IVncWOrZX70JIh2dWGwIF3ERU1OSi12NkigZ4VtdHNiYYPz[ZN{\WRiYYOgdIhwe3Cqb4L5cIF1cW:wIH;mJGdUUzOkZYThMEBKSzVyIE2gNE4{QCEQvF2u	NHr6OpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O5OFIyQCd-MkOzPVQzOTh:L3G+
MDA-MB-468	NXrwbW02TnWwY4Tpc44h[XO\|YYm=			M3:zSmlvcGmkaYTpc44hd2ZiQXv0JIlvKFCWRV6t[IVncWOrZX70JIh2dWGwIF3ERU1OSi12NkigZ4VtdHNiYYPz[ZN{\WRiYYOgdIhwe3Cqb4L5cIF1cW:wIH;mJHBTSVN2MDygTWM2OCB;IECuN\|kh\|ryPLh?=	NVnxcoJmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPVQzOThpPkKzN\|k1OjF6PD;hQi=>
BT474c	M{[3VWZ2dmO2aX;uJIF{e2G7			NXzYPWhCUW6qaXLpeIlwdiCxZjDBb5QhcW5iaIXtZY4hSlR2N{TjJINmdGy\|IHjhdoJwemmwZzDISXIzMy:SSVuzR2Eh\G:3YnzlJI12fGGwdDDhd5Nme3OnZDDhd{BxcG:\|cHjvdplt[XSrb36gc4YhT1ONM3LleIEtKEmFNUCgQUAxNjd4IN88UU4>	NH7CU4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O5OFIyQCd-MkOzPVQzOTh:L3G+
RT4	NEnPXW1HfW6ldHnvckBie3OjeR?=			MVrJcohq[mm2aX;uJI9nKFCNQTDpckBVW0NzIHTl[olkcWWwdDDoeY1idiCUVESgZ4VtdHNiYYPz[ZN{\WRiYYOgV\|YheGixc4Doc5J6dGG2aX;uMEBKSzVyIE2gNUDPxE1w	NWL6SGJlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPVQzOThpPkKzN\|k1OjF6PD;hQi=>
RT4	M2ezVGZ2dmO2aX;uJIF{e2G7			MX;Jcohq[mm2aX;uJI9nKFB5MGO2T{BqdiCWU1OxJIRm\mmlaXXueEBpfW2jbjDSWFQh[2WubIOgZZN{\XO\|ZXSgZZMhWzZicHjvd5Bpd3K7bHH0bY9vNCCLQ{WwJF0hPSEQvF2u	MkHvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|OUSyNVgoRjJ\|M{m0NlE5RC:jPh?=
PTEN-null LNCAP	MV3GeY5kfGmxbjDhd5NigQ>?		MlLNNUBpeg>?	M4K1OmlvcGmkaYTpc44hd2ZiQXv0JIlvKGi3bXHuJHBVTU5vboXscEBNVkODUDDj[YxteyCjc4Pld5Nm\CCjczDzeZBxemW\|c3nvckBqdiCSUlHTOFAheGixc4Doc5J6dGG2aX;uJIFnfGW{IEGgbJIh[nliRVzJV2Eh[W6jbInzbZMtKEmFNUCgQUAxNjN\|Nkig{txONg>?	NUOzdJo6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewPFkzOTFpPkK3NFg6OjFzPD;hQi=>
HCT116	NELJS4NCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MWK3NkBpenN?	Ml7jRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IEWuNkDPxE1w	M{LReFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEi5NlEyLz5{N{C4PVIyOTxxYU6=
OVCAR8	MmPiRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NX;mepZZPzJiaILz	Mlm3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCRVlPBVlgh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IEeuNlch\|ryPLh?=	NXuzU5JPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewPFkzOTFpPkK3NFg6OjFzPD;hQi=>
A673	M{KwV5FJXFNiYYPzZZk>			M2WwZpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy\|	MlfJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
DAOY	MmjldWhVWyCjc4PhfS=>			MorPdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN?	M{j2VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2	MkG2dWhVWyCjc4PhfS=>			NHLRTpNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-SH	MYfxTHRUKGG\|c3H5			NETDN3pyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1UUCClZXzsdy=>	NUK3cmZpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643	M2\JeZFJXFNiYYPzZZk>			M4TxNZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO=	MlzVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R)	MnK4dWhVWyCjc4PhfS=>			M{\FfpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?=	M{LTeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	MljHdWhVWyCjc4PhfS=>			NFHLWphyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?=	NIPSboo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	MnfwdWhVWyCjc4PhfS=>			MXvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	NXnxe5pbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1	MmTVdWhVWyCjc4PhfS=>			MmfldWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	NITpeHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
LAN-5	NHO5[ZRyUFSVIHHzd4F6			NFzSeWZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO=	M3yxPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18	NIHuVIZyUFSVIHHzd4F6			NVXT[pdFeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO=	NUTuephpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pAKT / AKT / pGSK3β / GSK3β; PubMed: 26998062 Oncol Lett AZD5363 inhibited the phosphorylation of GSK3β, but increased the phosphorylation of AKT in a time-dependent manner in the (A) Hep-G2 cells. HER3 / pHER3 / HER2 / pHER2 / pPRAS40 / pS6 / p-4EBP1 / pFOXO / pERK / PARP / Cleaved PARP; PubMed: 26095475 Int J Oncol (A) BT474c or HCC1954 cells were treated for 24 h with increasing concentrations of AZD5363 ±0.3 μM or 1 μM AZD8931, respectively. Protein lysates were analysed by immunoblot with the indicated antibodies. Blots are representative of blots from 2–3 separate experiments.	26998062 26095475
Immunofluorescence	p-Chk2 / γ-H2AX; PubMed: 29879757 Cancer Res Treat (C) Cells were treated with AZD1208 and AZD5363 alone or in combination for 5 days, and immunofluorescence analysis was subsequently performed. Confocal microscopy was used to observe the signals corresponding to p-Chk2 (red) and γ-H2AX (green). DAPI (blue) was used as a nuclear counterstain. CI, combination index. Scale bars=5 μm.	29879757
Growth inhibition assay	Cell viability; PubMed: 29879757 Cancer Res Treat Cells were seeded and cultured with increasing concentrations of AZD5363 and 1 μM AZD1208 every 3 days. The cells were cultured for 14 days until colonies formed and were then stained. The percentages of surviving cells were calculated by counting the number of colonies and are presented in a bar graph with standard error bars (n=3). a)p < 0.005.	29879757

In vivo

Oral dosing of AZD5363 (100, 300 mg/kg) to nude mice causes dose- and time-dependent reduction of PRAS40, GSK3β, and S6 phosphorylation in BT474c xenografts, reversible increases in blood glucose concentrations, and dose-dependent decreases in 2[¹⁸F]fluoro-2-deoxy-d-glucose (¹⁸F-FDG) uptake in U87-MG xenografts. Chronic oral dosing of AZD5363 (130, 200, and 300 mg/kg) causes dose-dependent growth inhibition of xenografts derived from various tumor types, including HER2+ breast cancer models that are resistant to trastuzumab. AZD5363 also significantly enhances the antitumor activity of docetaxel, lapatinib, and trastuzumab in breast cancer xenografts. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse Caliper Off-Chip Incubation Mobility Shift assay: The ability of AZD5363 and other compounds to inhibit the activity of AKT1, AKT2, and AKT3 is evaluated by the Caliper Off-Chip Incubation Mobility Shift assay. Active recombinant AKT1, AKT2, or AKT3 are incubated with a 5-FAM-labeled custom-synthesized peptide substrate together with increasing concentrations of inhibitor. Final reactions contained 1 to 3 nM AKT1, AKT2, or AKT3 enzymes; 1.5 mM peptide substrate; ATP at K _m for each AKT isoform; 10 mM MgCl₂, 4 mM DTT, 100 mM HEPES, and 0.015% Brij-35. The reactions are incubated at room temperature for 1 hour and stopped by the addition of buffer containing 100 mM HEPES, 0.015% Brij-35 solution, 0.1% coating reagent, 40 mM EDTA, and 5% DMSO. Plates are then analyzed using a Caliper LC3000, allowing for separation of peptide substrate and phosphorylated product by electrophoresis with subsequent detection and quantification of laser induced fluorescence.
Cell Research: ^[2]	- Collapse Cell lines: 182 solid and hematologic tumor cell lines Concentrations: ~30 μM Incubation Time: 72 hours Method: Cell proliferation assay is determined by 2 methods, MTS and Sytox Green. Briefly, cells are seeded in 96-well plates and incubated overnight at 37 ℃, 5% CO₂. Cells are then exposed to concentrations of AZD5363 ranging from 30 to 0.003μM for 72 hours. For the MTS endpoint, cell proliferation is measured by the CellTiter AQueous Non-Radioactive Cell Proliferation Assay reagent in accordance with the manufacturer's protocol. For the Sytox Green endpoint, Sytox Green nucleic acid dye diluted in TBS-EDTA buffer is added to cells (final concentration of 0.13 μM) and the number of dead cells detected using an Acumen Explorer. Cells are then permeabilized by the addition of saponin (0.03% final concentration, diluted in TBS-EDTA buffer), incubated overnight and a total cell count measured. Predose measurements are made for both MTS and Sytox Green endpoints, and concentration needed to reduce the growth of treated cells to half that of untreated cells values are determined using absorbance readings (MTS) or live cell counts. (Only for Reference)
Animal Research:^[2]	- Collapse Animal Models: Female nude mice and male SCID mice with BT474c, U87MG, KPL-4, HCC-1187 xenografts. Dosages: 130 mg/Kg - 300 mg/Kg Administration: p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	86 mg/mL (200.5 mM)
	Water	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Capivasertib (AZD5363) SDF

Molecular Weight	428.92
Formula	C₂₁H₂₅ClN₆O₂
CAS No.	1143532-39-1
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03310541	Active not recruiting	Drug: AZD5363\|Drug: Enzalutamide\|Drug: Fulvestrant	Breast Cancer\|Prostate Cancer\|Advanced Solid Tumors	Memorial Sloan Kettering Cancer Center	October 11 2017	Phase 1
NCT01992952	Active not recruiting	Drug: AZD5363\|Drug: Placebo\|Drug: Fulvestrant	Estrogen Receptor Positive Breast Cancer	Velindre NHS Trust\|AstraZeneca\|Cenduit LLC\|Covance\|Cardiff and Vale University Health Board	May 2014	Phase 1\|Phase 2
NCT02338622	Completed	Drug: olaparib\|Drug: AZD5363	Advanced Cancer	Royal Marsden NHS Foundation Trust\|Institute of Cancer Research United Kingdom\|AstraZeneca	March 31 2014	Phase 1
NCT02121639	Active not recruiting	Drug: Placebo\|Drug: AZD5363	Prostate Cancer	University Hospital Southampton NHS Foundation Trust\|AstraZeneca\|Cancer Research UK	January 29 2014	Phase 1\|Phase 2
NCT02077569	Completed	Drug: AZD5363	Invasive Breast Cancer	University of Nottingham\|AstraZeneca\|Cancer Research UK\|National Cancer Research Network	January 2014	Phase 2
NCT01692262	Completed	Drug: Intermittent dosing of AZD5363	Metastatic Castrate-Resistant Prostate Cancer (mCRPC)\|Efficacy\|Safety and Tolerability\|Pharmacokinetics\|Pharmacodynamics\|Tumour Response.	AstraZeneca	November 2012	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Selective Akt Inhibitor

CCT128930 : Akt2-selective, IC50=6 nM.
Most Potent Akt Inhibitor

GSK690693 : Akt1, IC50=2 nM; Akt2, IC50=13 nM; Akt3, IC50=9 nM.
Akt Inhibitor in Clinical Trial

Perifosine (KRX-0401) : Phase III for relapsed and refractory multiple myeloma.
Classic Akt Inhibitor

MK-2206 2HCl : Highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Related Akt Products

Afuresertib (GSK2110183) ^New

Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with K_i of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.
AT13148 ^New

AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.
SC79 ^New

SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. MK-2206 2HCl induces autophagy and apoptosis in cancer cells. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
Ipatasertib (GDC-0068)

Ipatasertib (GDC-0068, RG7440) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.
GSK690693

GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. GSK690693 also potently inhibits AMPK and DAPK3 from the CAMK family with IC50 of 50 nM and 81 nM, respectively. GSK690693 affects Unc-51-like autophagy activating kinase 1 (ULK1) activity, robustly inhibits STING-dependent IRF3 activation. Phase 1.
Perifosine (KRX-0401)

Perifosine (KRX-0401, NSC639966, D21266) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.
Triciribine (NSC 154020)

Triciribine (NSC 154020, VD-0002, vqd-002, API-2, TCN) is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.
Honokiol (NSC 293100)

Honokiol (NSC 293100) is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Honokiol causes G0/G1 phase arrest, induces apoptosis, and autophagy via the ROS/ERK1/2 signaling pathway. Honokiol inhibits hepatitis C virus (HCV) infection. Phase 3.

Choose Your Country or Region

By Signaling Pathways

By product type

Capivasertib (AZD5363)